experimental group:gefitinib combined with recombinant human endostatin

2 trials

Sponsors

Chengdu Fifth People's Hospital

Conditions

EGFR mutation positive late NSCLCEGFR mutation-positive advanced NSCLC

Phase 4

Clinical study of gefitinib combined with recombinant human endostatin or single-agent gefitinib in the treatment of EGFR mutation-positive advanced NSCLC

RecruitingChiCTR2000032148

Chengdu Fifth People's HospitalEGFR mutation positive late NSCLC

Start: 2020-05-01Updated: 2020-04-27

Clinical study of gefitinib combined with recombinant human endostatin or gefitinib in the first-line treatment of EGFR mutation positive advanced NSCLC

RecruitingChiCTR2000039905

Chengdu Fifth People's HospitalEGFR mutation-positive advanced NSCLC

Start: 2020-11-02Updated: 2021-02-22